Lantern Pharma Inc. (NASDAQ:LTRN)’s investigational drug LP-184 has achieved a major milestone in the fight against pediatric brain cancer, following independent validation by Johns Hopkins University researchers.
New preclinical data presented at the Society for Neuro-Oncology’s Pediatric Conference showed LP-184 extended survival dramatically in mouse models of atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive childhood brain cancer. In one model, median survival soared from 20 to 89 days, which is a 345% improvement, while another saw an increase from 68 to 98 days. The studies also confirmed strong anti-tumor activity across multiple ATRT subtypes and favorable blood-brain barrier penetration, with no apparent toxicity observed in treated animals.
A healthcare provider holding an MRI scan of a patient with a traumatic brain injury.
These results strengthen the scientific foundation for Lantern Pharma Inc.’s FDA Rare Pediatric Disease Designation for LP-184 in ATRT and pave the way for a planned pediatric clinical trial, expected to launch in late 2025 or early 2026.
LP-184, a next-generation acylfulvene drug, targets tumors with epigenetic dysregulation, such as those with SMARCB1 gene loss, a hallmark of ATRT. With current treatments offering poor outcomes and high toxicity, Lantern Pharma Inc.’s LP-184’s single-agent efficacy could mark a breakthrough for children facing this devastating diagnosis.
LTRN closed over 9% higher on May 29.
READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.
Hedge Fund Resource Center